News site default image

Gene-RADAR Authorized for Zika Testing: Interview with Nanobiosym Founder and CEO, Dr. Anita Goel

Shared by Radhika Narayanan | 0 0 0 | about 1 year ago

The World Health Organization reports that over 60 countries and territories suffer from continuing transmission of Zika, while the Centers for Disease Control (CDC) says that more than 40,000 people in the U.S. and its territories have been infected, including at least 4,750 pregnant women. With the growing danger of this infectious disease, and the impeding threat of neurological problems and brain damage it poses to developing babies, fast and accessible methods to screen for Zika and control its spread are urgently needed. One technology that promises to do so was the winner of the Nokia Sensing XCHALLENGE in 2013. Developed by Nanobiosym Inc., a Cambridge, MA firm, the Gene‐RADAR platform probes samples of bodily fluids placed on a “nanochip” and inserted into a portable device that rapidly reports the presence or absence of a pathogen. Following last week’s FDA Emergency Use Authorization of the Gene‐RADAR platform for Zika Testing, Medgadget had the chance to sit down with Nanobiosym’s founder and CEO, Dr. Anita Goel, a Harvard-MIT-trained physicist and physician.


Categories Interview Medtech & Devices

Related Post


0 Votes

You must log in to post a comment